Results 141 to 150 of about 89,048 (269)

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt, Paul Gray, Peter McNaughton, Jane Peake, Melanie Wong, George Aho, Emma Best, Maia Brewerton, Flora Lutui, Litara Esera Tulifau, Rebecca Qin, Satupa‘itea Viali, Petine White, Andrew Wood, See‐Tarn Woon, Theresa Cole, Alberto Pinzon Charry, Kuang‐Chih Hsiao   +17 more
wiley   +1 more source

Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)

Etoposide phosphate is a water-soluble prodrug of etoposide. A phase I and pharmacokinetic study has been performed over the dose range 25-110 mg/m(2)/day for 5 days (etoposide equivalent doses). The maximum tolerated dose (MTD) was 110 mg/m(2)/day for 5
D. R., M., K., Newell, C., Balmanno, Gumbrell, V., Igwemezie, L. N., Barbaiya, C. J., Simmonds, L., Chapman, McDaniel, Proctor, Millward, Taylor, F., Cantwell, D., Charlton, B., Kaul, Calvert, A. H., M. J., R. H., B. M. J., Lind, Winograd, Mummaneni, G. A., S.   +34 more
core  

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

NOVEL SELECTION AND GENETIC-CHARACTERIZATION OF AN ETOPOSIDE-RESISTANT HUMAN LEUKEMIC CCRF-CEM CELL-LINE

, 1993
Fisher, LM, LM Fisher, Patel, S, S Patel
core   +1 more source

Atypical Clinical Course of Griscelli Syndrome Type 2 With Primarily Neurologic Presentation and Adult‐Onset in a 46‐Year‐Old Male

American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1850-1855, August 2026.
ABSTRACT Griscelli Syndrome Type 2 (GS2) is a rare autosomal recessive disorder caused by pathogenic mutations in the RAB27A gene. Typically, it is characterized by cutaneous hypopigmentation, immunodeficiency, with or without neurological abnormalities secondary to hemophagocytic lymphohistiocytosis (HLH). Without treatment, GS2 often results in fatal
Dzhoy Papingi, Michael Kutsche, Helena Lichtenfeld, Fanny Kortüm, Angela Abicht, Laura Herrmann, Theresia Herget   +6 more
wiley   +1 more source

Cell-cell contact induced resistance to etoposide

, 2002
Many tumour cell lines grown in close three dimensional cell-cell contact either as multicell spheroids or tumours in mice exhibit a form of multicellular drug and radiation resistance that has been called the "contact effect". This resistance is often
Oloumi, Arusha
core  

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, EarlyView.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, Volume 159, Issue 3, Page 719-728, 1 August 2026.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Low Risk of Central Nervous System Relapse Among Patients With T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma Despite High‐Risk Disease Presentation

European Journal of Haematology, Volume 117, Issue 2, Page 358-365, August 2026.
ABSTRACT T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL) is a rare subtype of large B‐cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with
Atte Karhu, Sara Aronen, Aino Rönkä, Kaisa Sunela, Tuula Klaavuniemi, Annikki Aromaa‐Häyhä, Milla Kuusisto, Otto Jokelainen, Jan Böhm, Kristiina Vuolukka, Ulla‐Mari Arkko, Samuli Vaittinen, Minna Harmanen, Juha P. Väyrynen, Hanne Kuitunen, Sonja Nousiainen, Joonas Kuitunen, Juho Kangas, Eetu Pellonperä, Henri Kurttila, Miko Pietilä, Jaakko Tirkkonen, Outi Kuittinen   +22 more
wiley   +1 more source